Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage

Clinical Immunology

Volumn 155, Issue 2, 2014, Pages 220-230

  Tong, Li ^a   Nanjundaiah, Siddaraju M ^a   Venkatesha, Shivaprasad H ^a   Astry, Brian ^a   Yu, Hua ^a   Moudgil, Kamal D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Experimental arthritis; Mediators of inflammation; Natural products; T cell subsets (Th17 Treg); Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PRISTIMERIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; AUTACOID; CYTOKINE; TRITERPENE;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE INJURY; BONE REMODELING; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPH NODE CELL; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; PILOT STUDY; RAT; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH17 CELL; TISSUE INJURY; ANIMAL; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; SYNOVIUM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; BONE REMODELING; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 9; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; RATS; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; T-LYMPHOCYTE SUBSETS; TRITERPENES;

EID: 84910045434     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.09.014     Document Type: Article

References (58)

1. Lipsky P.E. Rheumatoid arthritis. Harrison's Principles of Internal Medicine 2008, 2083-2092. McGraw Hill New York, NY, USA New York. 17th edition. E.B.A. Fauci, E. Braunwald, D. Kasper, S. Hauser, D. Longo, J. Jameson, J. Loscalzo (Eds.).
2. Imboden J.B. The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 2009, 4:417-434.
3. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 2008, 118:3537-3545.
4. Feldmann M., Maini S.R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 2008, 223:7-19.
5. Astry B., Harberts E., Moudgil K.D. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J. Interferon Cytokine Res. 2011, 31:927-940.
6. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
7. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 2007, 56:1145-1151.
8. Kim E.Y., Chi H.H., Bouziane M., Gaur A., Moudgil K.D. Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma. Clin. Immunol. 2008, 127:98-106.
9. Rajaiah R., Puttabyatappa M., Polumuri S.K., Moudgil K.D. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J. Biol. Chem. 2011, 286:2817-2825.
10. Chaudhry A., Rudra D., Treuting P., Samstein R.M., Liang Y., Kas A., Rudensky A.Y. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
11. Huter E.N., Stummvoll G.H., DiPaolo R.J., Glass D.D., Shevach E.M. Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J. Immunol. 2008, 181:8209-8213.
12. Ogino H., Nakamura K., Ihara E., Akiho H., Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig. Dis. Sci. 2011, 56:376-386.
13. Duarte J., Agua-Doce A., Oliveira V.G., Fonseca J.E., Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One 2010, 5:e10558.
14. Lina C., Conghua W., Nan L., Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J. Clin. Immunol. 2011, 31:596-605.
15. Nistala K., Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009, 48:602-606.
16. Gibofsky A. Comparative effectiveness of current treatments for rheumatoid arthritis. Am. J. Manag. Care 2012, 18:S303-S314.
17. Schett G., Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 2012, 8:656-664.
18. Takayanagi H. New developments in osteoimmunology. Nat. Rev. Rheumatol. 2012, 8:684-689.
19. Anjubault T., Martin J., Hubert F.X., Chauvin C., Heymann D., Josien R. Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-kappaB ligand (RANK)-L by rat plasmacytoid dendritic cells. PLoS One 2012, 7:e33713.
20. Cantor H., Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 2009, 9:137-141.
21. Venkatesha S.H., Berman B.M., Moudgil K.D. Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorg. Med. Chem. 2011, 19:21-29.
22. Luo D.Q., Wang H., Tian X., Shao H.J., Liu J.K. Antifungal properties of Pristimerin and celastrol isolated from Celastrus hypoleucus. Pest Manag. Sci. 2005, 61:85-90.
23. Petronelli A., Pannitteri G., Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20:880-892.
24. Wang L.N., Wang Y., Lu Y., Yin Z.F., Zhang Y.H., Aslanidi G.V., Srivastava A., Ling C.Q., Ling C. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J. Integr. Med. 2014, 12:20-34.
25. Yadav V.R., Prasad S., Sung B., Kannappan R., Aggarwal B.B. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2010, 2:2428-2466.
26. Mu X., Shi W., Sun L., Li H., Jiang Z., Zhang L. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules 2012, 17:6854-6868.
27. Zhang L., Xu Z.J., Feng Y.J., Wang D.Y. Chemical constituents of roots of Celastrus orbiculatus. Zhong Yao Cai 2013, 36:569-572.
28. Costa P.M., Ferreira P.M., Bolzani Vda S., Furlan M., de Freitas Formenton Macedo Dos Santos V.A., Corsino J., de Moraes M.O., Costa-Lotufo L.V., Montenegro R.C., Pessoa C. Antiproliferative activity of Pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol. In Vitro 2008, 22:854-863.
29. Yu H., Yang Y.H., Rajaiah R., Moudgil K.D. Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anti-cyclic citrullinated peptide antibodies. Arthritis Rheum. 2011, 63:981-991.
30. Venkatesha S.H., Yu H., Rajaiah R., Tong L., Moudgil K.D. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J. Biol. Chem. 2011, 286:15138-15146.
31. Nanjundaiah S.M., Stains J.P., Moudgil K.D. Kinetics and interplay of mediators of inflammation-induced bone damage in the course of adjuvant arthritis. Int. J. Immunopathol. Pharmacol. 2013, 26:37-48.
32. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987, 2:595-610.
33. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., Wu C., Kleinewietfeld M., Kunder S., Hafler D.A., Sobel R.A., Regev A., Kuchroo V.K. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13:991-999.
34. Zuniga L.A., Jain R., Haines C., Cua D.J. Th17 cell development: from the cradle to the grave. Immunol. Rev. 2013, 252:78-88.
35. Franco G.C., Kajiya M., Nakanishi T., Ohta K., Rosalen P.L., Groppo F.C., Ernst C.W., Boyesen J.L., Bartlett J.D., Stashenko P., Taubman M.A., Kawai T. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Exp. Cell Res. 2011, 317:1454-1464.
36. Grassi F., Cristino S., Toneguzzi S., Piacentini A., Facchini A., Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J. Cell. Physiol. 2004, 199:244-251.
37. Adhikary S., Kocieda V.P., Yen J.H., Tuma R.F., Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 2012, 120:3741-3749.
38. Hu Y., Ivashkiv L.B. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J. Immunol. 2006, 176:6022-6033.
39. Fonseca J.E., Canhao H., Tavares N.J., Cruz M., Branco J., Queiroz M.V. Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1year. Clin. Rheumatol. 2009, 28:1213-1216.
40. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijde D., Breedveld F.C., Furst D.E., Lipsky P.E. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005, 52:1020-1030.
41. Astry B.C., Venkatesha S.H., Moudgil K.D. Celastrus-derived Celastrol modulates autoimmune arthritis through cellular immunoregulation. Immunity & Tolerance: 78th Cold Spring Harbor Symposium on Quantitative Biology May 2013, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory, New York, (Abstract # 19).
42. Hansen E.S., Medic V., Kuo J., Warner T.F., Schell R.F., Nardelli D.T. IL-10 inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis. Infect. Immun. 2013, 81:4421-4430.
43. Huang Q.Q., Koessler R.E., Birkett R., Perlman H., Xing L., Pope R.M. TLR2 deletion promotes arthritis through reduction of IL-10. J. Leukoc. Biol. 2013, 93:751-759.
44. Lin B., Zhang H., Zhao X.X., Rahman K., Wang Y., Ma X.Q., Zheng C.J., Zhang Q.Y., Han T., Qin L.P. Inhibitory effects of the root extract of Litsea cubeba (lour.) pers. on adjuvant arthritis in rats. J. Ethnopharmacol. 2013, 147:327-334.
45. Yang Y.H., Rajaiah R., Lee D.Y., Ma Z., Yu H., Fong H.H., Lao L., Berman B.M., Moudgil K.D. Suppression of ongoing experimental arthritis by a Chinese herbal formula (Huo-Luo-Xiao-Ling Dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation. Evid. Based Complement. Alternat. Med. 2011, 2011:642027.
46. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 2006, 66:4816-4825.
47. Sundaram K., Nishimura R., Senn J., Youssef R.F., London S.D., Reddy S.V. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp. Cell Res. 2007, 313:168-178.
48. Yao J.S., Zhai W., Young W.L., Yang G.Y. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem. Biophys. Res. Commun. 2006, 342:1396-1404.
49. Zhang F., Tanaka H., Kawato T., Kitami S., Nakai K., Motohashi M., Suzuki N., Wang C.L., Ochiai K., Isokawa K., Maeno M. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 2011, 93:296-305.
50. Kim J.L., Kang S.W., Kang M.K., Gong J.H., Lee E.S., Han S.J., Kang Y.H. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts. J. Cell. Biochem. 2012, 113:247-259.
51. Tao X., Younger J., Fan F.Z., Wang B., Lipsky P.E. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002, 46:1735-1743.
52. Wang B., Ma L., Tao X., Lipsky P.E. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum. 2004, 50:303-2995.
53. Tong L., Moudgil K.D. Celastrus aculeatus Merr. suppresses the induction and progression of autoimmune arthritis by modulating immune response to heat-shock protein 65. Arthritis Res. Ther. 2007, 9:R70.
54. Cascao R., Vidal B., Raquel H., Neves-Costa A., Figueiredo N., Gupta V., Fonseca J.E., Moita L.F. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun. Rev. 2012, 11:856-862.
55. Shen C.L., von Bergen V., Chyu M.C., Jenkins M.R., Mo H., Chen C.H., Kwun I.S. Fruits and dietary phytochemicals in bone protection. Nutr. Res. 2012, 32:897-910.
56. Ahmed S., Marotte H., Kwan K., Ruth J.H., Campbell P.L., Rabquer B.J., Pakozdi A., Koch A.E. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14692-14697.
57. Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., Mukhtar H. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4524-4529.
58. Cheng C.W., Fan W., Ko S.G., Song L., Bian Z.X. Evidence-based management of herb-drug interaction in cancer chemotherapy. Explore (NY) 2010, 6:324-329.